Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Mar 2026 is 10.25% vs 17.53% in Mar 2025
Consolidate Net Profit
YoY Growth in quarter ended Mar 2026 is 392.74% vs -154.39% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Mar 2026 is 5.65% vs 31.32% in Mar 2025
Interest
YoY Growth in quarter ended Mar 2026 is -100.00% vs 0.00% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025
Compare Quarterly Results Of Xvivo Perfusion AB With
Quarterly - Net Sales
QoQ Growth in quarter ended Mar 2026 is 6.59% vs 19.57% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 10.25% vs 17.53% in Mar 2025
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Mar 2026 is 14.87% vs 634.88% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 392.74% vs -154.39% in Mar 2025
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Mar 2026 is -10.46% vs 55.37% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 5.65% vs 31.32% in Mar 2025
Quarterly - Interest
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025
YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025






